Analyst Thinks This Company’s Bone Marrow Cancer Treatment Can ‘Transform Paradigm’
SVB Leerink initiated coverage on CTI Biopharma Corp (NASDAQ:CTIC) with an Outperform rating and a $13 price target. CTIC is a commercial-stage…
Where CTI BioPharma Stands With Analysts
Within the last quarter, CTI BioPharma (NASDAQ:CTIC) has observed the following analyst ratings:
SVB Leerink Initiates Coverage On CTI BioPharma with Outperform Rating, Announces Price Target of $13
SVB Leerink analyst Andrew Berens initiates coverage on CTI BioPharma (NASDAQ:CTIC) with a Outperform rating and announces Price Target of $13.
CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting
CTI BioPharma Corp. (NASDAQ:CTIC) today announced two poster presentations from the Company's pacritinib program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting, to be held in Houston,
CORRECTION: Jefferies Initiates Coverage On CTI BioPharma with Buy Rating, Announces Price Target of $13 – Correct Analyst Firm Updated
CORRECTION:Jefferies analyst Kelly Shi initiates coverage on CTI BioPharma (NASDAQ:CTIC) with a Buy rating and announces Price Target of $13, correct Analyst Firm updated.
JP Morgan Initiates Coverage On CTI BioPharma with Buy Rating, Announces Price Target of $13
JP Morgan analyst Kelly Shi initiates coverage on CTI BioPharma (NASDAQ:CTIC) with a Buy rating and announces Price Target of $13.
CTI BioPharma’s Return On Capital Employed Overview
According to data from Benzinga Pro, during Q2, CTI BioPharma's (NASDAQ:CTIC) reported sales totaled $12.33 million. Despite a 39.06% increase in earnings, the company posted a loss of $22.65 million.
CTI BioPharma Shares See Volume, Co. Awarded 5-Year Veterans Affairs Federal Supply Schedule Contract Initially Worth $3M
https://sam.gov/opp/44309ba1c7314c06ae11806e3b0f8280/view
Tesla, Coinbase And Some Other Big Stocks Moving Lower In Today’s Pre-Market Session
Uxin Limited (NASDAQ: UXIN) shares dropped 9.6% to $0.61 in pre-market trading. Uxin, last month, posted Q4 EPS of $0.05.
Needham Maintains Buy on CTI BioPharma, Raises Price Target to $9
Needham analyst Gil Blum maintains CTI BioPharma (NASDAQ:CTIC) with a Buy and raises the price target from $8 to $9.